Most-Read Life Science Tools & Diagnostics Notes by the Buy Side: June 2026

Research evidence excerpt

Most-Read Life Science Tools & Diagnostics Notes by the Buy Side: June 2026

Life Science Tools & Diagnostics

Equity Research

June 30, 2026

Jefferies Financial Group Inc., its affiliates or subsidiaries is acting as a manager or co-manager in the underwriting or placement of securities for Guardant

Health Inc or one of its affiliates.

Within the past twelve months, Guardant Health Inc has been a client of Jefferies Financial Group Inc., its affiliates or subsidiaries and investment banking

services are being or have been provided.

Explanation of Jefferies Ratings

Buy - Describes securities that we expect to provide a total return (price appreciation plus yield) of 15% or more within a 12-month period.

Hold - Describes securities that we expect to provide a total return (price appreciation plus yield) of plus 15% or minus 10% within a 12-month period.

Underperform - Describes securities that we expect to provide a total return (price appreciation plus yield) of minus 10% or less within a 12-month period.

The expected total return (price appreciation plus yield) for Buy rated securities with an average security price consistently below $10 is 20% or more within a 12-

month period as these companies are typically more volatile than the overall stock market. For Hold rated securities with an average security price consistently

below $10, the expected total return (price appreciation plus yield) is plus or minus 20% within a 12-month period. For Underperform rated securities with an

average security price consistently below $10, the expected total return (price appreciation plus yield) is minus 20% or less within a 12-month period.

NR - The investment rating and price target have been temporarily suspended.